Skip to main content
Log in

The treatment of postmenopausal women with advanced breast cancer with buserelin

  • Original Articles
  • Breast Cancer, Buserilin
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Repeated administration of long-acting analogues of gonadotrophin-releasing hormone down-regulates the pituitary gonadotrophins and gonadal hormones. The activity of these compounds in premenopausal women with breast cancer has been previously noted. In an attempt to cause a highly selective medical hypophysectomy 18 consecutive postmenopausal women with symptomatic advanced breast cancer were treated with intranasal buserelin in divided dosages of either 600 or 1000 μg daily. The pituitary gonadotrophins were suppressed in all patients, without objective evidence of response. This is in contrast with an earlier finding that the long-acting analogues of gonadotrophin-releasing hormone were effective in postmenopausal patients with breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bates T, Rubens RD, Bulbrook RD et al (1976) Comparison of pituitary function and clinical response after transphenoidal and transfrontal hypophysectomy for advanced breast cancer. Eur J Cancer 12:775–782

    Google Scholar 

  2. Beatson GT (1896a) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107

    Google Scholar 

  3. Beatson GT (1896b) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet II:162–165

    Google Scholar 

  4. Fattah DI, Chard T (1981) Method for measuring sex hormone binding globulin. Clin Chem 27:1277–1279

    Google Scholar 

  5. Harvey HA, Lipton A, Santen RJ et al. (1981) Phase II study of a gonadotropin releasing hormone analogue in postmenopausal advanced breast cancer. Proc Am Soc Clin Oncol C436

  6. Klijn JGM, De Jong FH (1982) Treatment with a luteinizing hormone-releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1:1213–1216

    Google Scholar 

  7. La Rossa JT, Strong MS, Melby JC (1978) Endocrinologically incomplete transphenoidal hypophysectomies with relief of bone pain in breast cancer. N Engl J Med 298:1332–1335

    Google Scholar 

  8. Manni A, Pearson OH, Brodkey J, Marshall JS (1979) Transphenoidal hypophysectomy in breast cancer. Cancer, 44: 2330–2337

    Google Scholar 

  9. McMillin JM, Seal US, Theologides A (1977) Prolactin dynamics following transphenoidal hypophysectomy for metastatic carcinoma of the breast. Cancer 39:2254–2257

    Google Scholar 

  10. Nillius S-J, Bergquist C, Wide L (1978) Inhibition of ovulation, in women by chronic treatment with a stimulatory LRH analogue — a new approach to birth control? Contraception 17:537–545

    Google Scholar 

  11. Schinzinger (1889) Über Carcinoma Mammae (abst) Zbl Chir 16:55

    Google Scholar 

  12. Wang DY, Bulbrook RD, Rubens RD et al. (1976) Comparison of pituitary function and clinical response after transphenoidal and transfrontal hypophysectomy for advanced breast cancer. Eur J Cancer 12:775–782

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waxman, J.H., Harland, S.J., Coombes, R.C. et al. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother. Pharmacol. 15, 171–173 (1985). https://doi.org/10.1007/BF00257531

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257531

Keywords

Navigation